Choi In-young, Head of Hanmi 바카라 찍어먹기 배팅 R&D Center, at press conference: “We will launch an obesity drug that overcomes the limitations of GLP-1-based treatments”
[by Kang, In Hyo] “I was so busy with business meetings that I barely had time to eat. I gained a lot of attention at this year’s 바카라 찍어먹기 배팅 Morgan Healthcare Conference and was able to confirm that the differentiating factor we had in mind was indeed accurate.”
Choi In-young, head of Hanmi 바카라 찍어먹기 배팅’s R&D Center, mentioned at a press conference during the 2025 JP Morgan Healthcare Conference, the world’s largest 바카라 찍어먹기 배팅 and biotechnology investment event held in San Francisco, USA, on January 15 (local time), “We will present an obesity treatment that addresses the limitations of ‘glucagon-like peptide 1 (GLP-1)’-based drugs, which inevitably cause muscle loss.”
Hanmi 바카라 찍어먹기 배팅 is advancing GLP-1-based obesity treatments, such as ‘Efpeglenatide’, alongside the triple-acting candidate ‘HM15275’ (development code name). Notably, ‘HM17321’ is a treatment designed to prevent muscle loss while inducing weight loss, with a mechanism that increases the number of muscle cells.
Choi outlined their strategy, emphasizing, 'The key is to develop drugs tailored to each patient’s unique characteristics.” He added, “Efpeglenatide is a typical choice for obese patients with a high risk of cardiovascular disease, while triple-agent drugs are more suited for patients with fatty liver issues. As the 바카라 찍어먹기 배팅 market evolves, it will be crucial to position drugs in a way that aligns with thir specific characteristics.”
Choi highlighted that the key advantage of HM17321, which Hanmi 바카라 찍어먹기 배팅 is promoting as a next-generation obesity drug candidate, is its ability to mitigate the side effect of ‘muscle loss’ when used in combination with existing obesity drugs. “HM17321’s greatest strength is its compatibility with GLP-1-based obesity drugs,” he noted. “It can also be administered in a single syringe.”
At present, the multinational 바카라 찍어먹기 배팅 company Eli Lilly is also running a combination clinical trial aimed at developing a treatment that preserves muscle mass. However, this treatment is antibody-based. In 2023, Eli Lilly acquired Versanis Bio for approximately USD 1.9 billion, gaining control of the sarcopenia drug 'bimagrumab.' The aim is to preserve muscle mass while enhancing weight loss effects by co-administering bimagrumab and GLP-1 obesity drugs.
"Antibody drugs are extremely expensive," Choi explained. "Our drug is peptide-based, and HM17321 can be injected subcutaneously, similar to GLP-1-based drugs, allowing for self-administration and ensuring competitive pricing."
Lastly, Choi mentioned that with the resolution of the year-long management rights dispute at Hanmi 바카라 찍어먹기 배팅, the company can now focus more on research and development (R&D). "I don't believe there should be any concerns about Hanmi 바카라 찍어먹기 배팅s' R&D performance this year, and I expect many positive developments," he remarked. "The R&D Center’s budget has seen a significant increase this year, accompanied by a 30% growth in R&D staff."
“We have also initiated cell-based gene therapy (CGT), and research into new modalities (바카라 찍어먹기 배팅 approaches), such as messenger ribonucleic acid (mRNA), antibody-drug conjugates (ADC), and targeted protein degraders (TPD), is expanding,” Choi further emphasized.